Unknown

Dataset Information

0

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?


ABSTRACT: The high recurrence rate and the low overall survival in ovarian cancer suggest that a more specific therapeutic approach in addition to conventional treatment is required. Translational and clinical research is investigating new molecular targets in order to find an alternative way to affect tumor growth and to minimize the overlap of toxicity of antiblastic agents. Given its implication in many cellular activities including regulation of cell growth, motility, survival, proliferation, protein synthesis, autophagy, transcription, as well as angiogenesis, PI3K/AKT/mTOR is one of the most investigated intracellular signaling pathways. A dis-regulation of this pathway has been shown in several tumors, including ovarian cancer. In this setting, mTor proteins represent a potential target for inhibitors, which could ultimately play a pivotal role in counteracting cellular proliferation. Recently, mTor inhibitors have been approved in the treatment of pancreatic neuroendocrine tumors, mantle cell lymphoma and renal cancer. Clinical trials have assessed the safety of these drugs in ovarian cancer patients. Ongoing phase I and II studies are evaluating the oncologic outcome of mTor inhibitor treatment and its effect in combination with conventional chemotherapy and target agents.

SUBMITTER: Gasparri ML 

PROVIDER: S-EPMC5658232 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Gasparri Maria Luisa ML   Bardhi Erlisa E   Ruscito Ilary I   Papadia Andrea A   Farooqi Ammad Ahmad AA   Marchetti Claudia C   Bogani Giorgio G   Ceccacci Irene I   Mueller Michael D MD   Benedetti Panici Pierluigi P  

Geburtshilfe und Frauenheilkunde 20171026 10


The high recurrence rate and the low overall survival in ovarian cancer suggest that a more specific therapeutic approach in addition to conventional treatment is required. Translational and clinical research is investigating new molecular targets in order to find an alternative way to affect tumor growth and to minimize the overlap of toxicity of antiblastic agents. Given its implication in many cellular activities including regulation of cell growth, motility, survival, proliferation, protein  ...[more]

Similar Datasets

| S-EPMC4302085 | biostudies-literature
| S-EPMC9377914 | biostudies-literature
| S-EPMC4203662 | biostudies-literature
| S-EPMC10970097 | biostudies-literature
| S-EPMC8223286 | biostudies-literature
| S-EPMC7485720 | biostudies-literature
| S-EPMC7213295 | biostudies-literature
| S-EPMC8304822 | biostudies-literature
| S-EPMC10003259 | biostudies-literature
| S-EPMC5529984 | biostudies-other